Efficacy and Safety of B/F/TAF in HIV-1 and HBV Coinfection

This document is a research report detailing the results of the ALLIANCE study, a Phase 3, randomized, double-blind trial comparing the efficacy and safety of B/F/TAF versus DTG + F/TDF in treatment-naïve adults with both HIV-1 and hepatitis B virus (HBV) coinfection over a period of 96 weeks. The study found that both treatment regimens achieved high rates of viral suppression for HIV-1 and HBV. Notably, B/F/TAF demonstrated superior rates of HBeAg loss and seroconversion compared to DTG + F/TDF. Additionally, other markers of anti-HBV activity, such as ALT normalization and HBsAg loss, showed favorable trends for B/F/TAF. The report also includes demographic characteristics of participants, safety profiles, and adverse events observed during the study. Overall, the findings suggest that B/F/TAF may offer clinical benefits for adults initiating antiviral therapy for HIV-1 and HBV coinfection.